Furthermore, given its cell surface localization and functional role in tumor biology, Claudin-4 represents an attractive therapeutic target, as evidenced by ongoing clinical trials and early translational studies investigating Claudin-targeted antibodies and ADCs in gastrointestinal and gynecologic cancers [43]. The gene discussed is CLDN4; the disease is female reproductive organ cancer.